ArticleCancer reports (Hoboken, N.J.)2025
Identification of Tumor Antigens and Immune Subtypes in Hepatocellular Carcinoma From a Multiomics Perspective.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hepatocellular carcinoma metastasis-immune microenvironment crosstalk: emerging mechanisms and immunotherapy.Cellular & molecular biology letters · 2026Review
- Identification of Tumor Antigens and Immune Subtypes in Hepatocellular Carcinoma From a Multiomics Perspective.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundImmunotherapies including immune checkpoint inhibitors and tumor antigen based vaccines have revolutionized cancer treatment. However, immune signatures of hepatocellular carcinoma (HCC) have not been thoroughly studied from a multiomics perspective.
aimsIn this study, we aimed to identify the potential tumor antigens and immune subtyping for HCC using multiomics data. METHODS AND
resultsThe study included 159 HCC patients with genome, transcriptome, proteome, and phosphoproteome data. Two potential tumor antigens, ZNF831 and SYNE1, showed significant superior prognostic effects and positive correlations with antigen presenting cells, which provided promising candidates for the development of tumor antigen-based mRNA vaccine. A multiomics clustering using the most variable tumor antigen genes of transcriptome, proteome, and phosphoproteome was performed, resulting in two HCC subtypes with distinct clinical and molecular features. In order to further explore the complex tumor microenvironment, we implemented an immune subtyping using 30 most important immune-related features generated from the random forest algorithm. Four immune subtypes were constructed, which exhibited diverse molecular attributes including immune cell activities, angiogenesis, cell proliferation, and the expression of tumor antigen genes, immune checkpoints, and immunogenic cell death modulators.
conclusionIn summary, we found two potential tumor antigens, ZNF831 and SYNE1, and identified four immune subtypes of HCC with distinct molecular features. Our study provides novel insights into the development of cancer vaccine and precision medicine of immune oncology in HCC, which may benefit clinical practice in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.